




Achieving financial and societal returns: Are all charitable and social investment returns equal?

26 January 2017

Chair	Anne-Marie Piper, Head of Charities, Farrer & Co.
Panel	William Reid, Head of Charities, Quilter Cheviot
	Keith Ward, Head of Social Impact Advisory, RSM
	Hilary Evans, Chief Executive, Alzheimer's Research UK
	Paul Blyth, Investment Director, Panahpur

Philanthropy Impact Investment Continuum



The chart above reflects returns from the perspective of the investee and their impact - societal and/or financial.

Investors including intermediaries would decide on the appropriate investment mix depending on their objectives for capital and their values.

Donor Journey





Financial investment v societal investment

Keith Ward

Head of Social Impact Advisory - RSM




RSM consultancy – social impact advisory

- RSM is one of the leading firms of chartered accountants involved in measuring social impact.
- It's All About Me
 - First social impact bond for voluntary adoption agencies working with local authorities.
 - £5m fund to support challenging adoptions.
- Contributed to the European Commission review of social impact.
- Carried out over 50 social impact reviews, including:
 - national and local charities
 - evaluations of local authority arms length/partnership leisure trusts;
 - healthcare evaluations Horder Healthcare, Carers Support Centre;
 - social housing.



Social Impact – What is it?

- The impact of your actions on society; impact can be value created or a cost saved!
- Value created: community of volunteers, social interaction, tenant 'wellbeing', maintaining/increasing local spending, higher levels of educational attainment
- It can be identified, mapped, measured, recorded, modelled and evaluated or it can just be used to tell a story.



Social impact is a powerful tool

- It can methodically demonstrate, in a comparable way, the huge difference philanthropic support makes - it can shine a unique light and be used to differentiate funding applications
- So why not universally applauded and used up and down the land?
- Is it robust enough to support real funding decisions or is it too judgemental?



There are many challenges....

- 1. It is subjective people like black and white
- 2. Multitude of approaches
- 3. Understand the theory of change & managing expectations
- 4. Proxy values and ease of calculation
- 5. Develop financial proxies
- 6. Building an evidence base
- 7. Difficulties in getting started
- 8. Is it right?



But may be if we compared to financial statements....

- Financial statements only claim to be true and fair.
- Financial statements have transparent assumptions look at any pension note!
- Auditors define materiality what the accounts may be wrong by before it affects your view!
- If social impact reports shouted out this number is not correct, but it gives a unique insight into what has happened would they gain greater legitimacy...and usage!



Achieving financial and societal returns: Are all charitable and social investment returns equal?

Hilary Evans Chief Executive, Alzheimer's Research UK



The Power to Defeat Dementia

What does Alzheimer's Research UK do?




A world free from the fear, harm and heartbreak of dementia



The Power to Defeat Dementia

ARUK Projects – creating opportunities



BRAINS FOR DEMENTIA RESEARCH


Increasing knowledge - Finding a cure

A partnership between Alzheimer's Research UK and Alzheimer's Society In association with the Medical Research Council

Making a discovery

Understanding the biology of diseases that cause dementia

- Is this process important in the disease?
- Could it be a target for new treatments?



Libraries of chemicals are screened to find those that could be developed into experimental drugs.



One step towards the clinic

Hit compounds go through many rounds of tweaking and re-testing.

- Does it work in a living system?
- Does it have good drug properties?



Validating the discovery

more closely.

Potential targets are studied

- What does the target do?

- Can we test it in the lab?

Developing hits 4 to leads

Hit compounds are modified by chemists to improve their properties and activity.

Clinical trials 6

Potential new treatments must pass through three phases of clinical trials in people to test if they are safe and effective

Where is Alzheimer's Research UK making a difference?



Our grant schemes fund all stages of the process with many focusing on the earliest discoveries.



Our Drug Discovery Alliance, Dementia Consortium and Stem Cell Research Centre focus on turning these discoveries into promising leads.




Our Global Clinical Trials Fund has the potential to take the best leads into the clinic.

Dementia Consortium

Spotted opportunity – lack of investment from Pharma Potential for future IP



DEMENTIA Consortium





First for dementia

- Important and highly challenging area
- Focus on increasing investment / success in field

Risk sharing

Attraction for pharma

Fund manager – SVLS

High calibre, proven track record of deal sourcing and success

Programme Related Investment (PRI) – fulfils charity remit



ARUK INVESTMENTS



ARUK Investments

- The number of research commitments which we can make is governed by our reserves policy which does not allow us to over commit.
- Our reserves policy requires us to hold sufficient working capital to cover six months operating costs and a minimum of twelve months research commitments or a maximum of twenty four months research commitments.
- Key driver is using expert advisers to advise on which investments to make having given them detailed guidance within a policy on acceptable risk and ethical guidelines.
- Importance of high quality Advice and strong Treasurer to head charity Investment Committee.



Ethics of Charity Investment

Charity Commission encourages ethical policy.

If the Trustees decide they are going to have an ethical policy they have to be able to demonstrate why they are investing in that way. The law permits the following reasons:

- A particular investment conflicts with the aims of the charity.
- The charity might lose support or beneficiaries if it does not invest ethically.
- There is no significant financial detriment.



Thank-you



The Power to Defeat Dementia





Achieving financial and societal returns: Are all charitable and social investment returns equal?

26 January 2017

Chair	Anne-Marie Piper, Head of Charities, Farrer & Co.
Panel	William Reid, Head of Charities, Quilter Cheviot
	Keith Ward, Head of Social Impact Advisory, RSM
	Hilary Evans, Chief Executive, Alzheimer's Research UK
	Paul Blyth, Investment Director, Panahpur